Physician profile
Michael N Moore
NPI 1639120447
$612.86
in general payments reported to CMS, 2019-2025
16 companies · $90.12 in 2025
The $90.12 reported for 2025 was more than what a typical Anesthesiology provider received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.38 · 2020: $50.44 · 2021: $94.83 · 2022: $20.92 · 2023: $137 · 2024: $205 · 2025: $90.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $432.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $159.87 | 2022-2024 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $90.63 | 2021-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.45 | 2020-2024 | Trulance, Xifaxan |
| Dexcom, INC. | $36.57 | 2024-2025 | Dexcom G6 Transmitter |
| Vivus LLC | $34.61 | 2021-2023 | Qsymia |
| Regeneron Healthcare Solutions, INC. | $29.94 | 2024 | Dupixent |
| Abbvie INC. | $27.73 | 2025 | |
| Merck Sharp & Dohme LLC | $26.50 | 2024 | Dificid |
| Madrigal Pharmaceuticals | $25.88 | 2025 | Rezdiffra |
| Astellas Pharma US INC | $22.21 | 2020 | |
| Braintree Laboratories, INC. | $20.93 | 2021 | |
| Intercept Pharmaceuticals, INC. | $20.36 | 2023 | Ocaliva |
| Trevena, INC. | $15.68 | 2021 | |
| Nestle Healthcare Nutrition INC. | $15.48 | 2021 | |
| Lundbeck LLC | $14.38 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $13.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.